Babu Yarlagadda S's Form 4 filing
Biocryst Pharmaceuticals Inc (BCRX) · filed Dec 9, 2021
- Accession no.
- 0001127602-21-030610
- Filed
- Dec 9, 2021
- Trade date
- Dec 7, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $367.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Babu Yarlagadda SCIK 0001452635 | Officer (Chief Discovery Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 7, 2021 | Common Stock | MOption exerciseAcquired | +62,000 | $4.73 | +$293,260 | 245,156 | Direct | |
| Dec 7, 2021 | Common Stock | SSaleDisposed | −30,100 | $12.20 | −$367,220 | 215,056 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 7, 2021 | Common Stock | MOption exerciseDisposed | −62,000 | $0.00 | $0 | 0 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.